Key result
Specific plasma microRNA signatures are linked to increased risks of 3P-major cardiovascular events and cardiovascular death.
Why the study?
The associations between plasma microRNA levels and major adverse cardiovascular events in a prospective epidemiological cohort were not well established.
Are circulating plasma microRNA levels associated with the future risk of 3P-MACE and CVD death in an epidemiological cohort?
Case-Control (n=479)
Are circulating plasma microRNA levels associated with the future risk of 3P-MACE and CVD death in an epidemiological cohort?
Answers are grounded in this paper and cite their sources.
Specific differentially expressed plasma microRNAs are significantly associated with future 3P-MACE and cardiovascular death, supporting their potential as predictive cardiovascular biomarkers.
Circulating microRNAs (miRNAs) are promising biomarkers of cardiovascular disease (CVD) and three-point major adverse cardiovascular events (3P-MACE): CVD death, non-fatal myocardial infarction (MI), and non-fatal stroke. The associations between plasma miRNA levels and 3P-MACE in a prospective cohort from an epidemiological study were evaluated. This nested case–control study included 479 participants: 166 cases with 3P-MACE and 313 controls matched individually for sex, exact baseline age, and region of residence. Median follow-up was 10.4 years [7.0; 11.7]. Total RNA was isolated from EDTA plasma using the miRNeasy Serum/Plasma Advanced Kit. Libraries were prepared with the QIAseq miRNA UDI Library Kit and sequenced on a NextSeq 550 (1 × 75 bp). After adjustment for six and twelve preanalytical and clinical covariates, eleven and five differentially expressed (DE) miRNAs retained significant associations with 3P-MACE or CVD death, respectively. Although these findings support plasma miRNA profiles as potential MACE biomarkers, all DE miRNAs remain exploratory. Further studies in larger independent populations with cross-validation are required before integration with traditional risk markers to predict future MACE.
No takes yet. Share an insight, caveat, or question.
Kiseleva et al. (2026) conducted a case-control in Major Adverse Cardiovascular Events (3P-MACE) (n=479). Plasma microRNA levels vs. Matched controls without 3P-MACE was evaluated on 3-point major adverse cardiovascular events (3P-MACE: CVD death, non-fatal MI, and non-fatal stroke) or CVD death. Plasma microRNA levels were associated with adverse outcomes, with 11 and 5 differentially expressed miRNAs linked to 3P-major cardiovascular events and CVD death, respectively, after covariate adjustment.
Synapse has enriched 10 related papers. Consider them for comparative context: